文献速递骨质疏松与代谢性骨病

罗莫佐单抗探索性治疗Hajdu-Cheney综合征患者骨质疏松:一例病例报告

Exploratory use of romosozumab for osteoporosis in a patient with Hajdu-Cheney syndrome: a case report.
PubMed 文献 · Osteoporos Int · 2023-01-09

报告一例43岁女性Hajdu-Cheney综合征(HCS)伴骨质疏松患者,NOTCH2基因6758G>A突变致Trp2253Ter。因已用双膦酸盐超过10年,启用罗莫佐单抗治疗1年,腰椎、股骨颈、全髋骨密度分别增加10.2%、6.3%、1.3%,末端骨溶解未恶化,为可能的治疗选择。

要点

  • HCS由NOTCH2基因突变引起,全球尚无既定治疗指南。
  • 罗莫佐单抗治疗1年后腰椎骨密度增加10.2%,股骨颈增加6.3%,全髋增加1.3%。
  • 治疗1年末端骨溶解维持原状未恶化,作者认为可能为HCS的治疗选择。

核心结论

  • 罗莫佐单抗治疗1年为HCS伴骨质疏松患者带来显著骨密度增益,并维持末端骨溶解状态未恶化,作者认为可能为HCS的治疗选择。
  • 这是韩国首例报道的罗莫佐单抗治疗HCS伴骨质疏松的病例。

研究设计与样本

  • 个案病例报告:一例43岁女性HCS伴骨质疏松患者,因已在其他医院接受双膦酸盐治疗超过10年而启用罗莫佐单抗。
  • 通过下一代测序确认NOTCH2基因核苷酸6758G>A突变导致Trp2253Ter替换。

主要发现

  • 罗莫佐单抗治疗1年后,腰椎、股骨颈、全髋骨密度分别增加10.2%、6.3%、1.3%,Z值分别为-2.9、-1.6、-1.2。
  • C末端肽抑制26.4%(0.121降至0.089 ng/mL),I型前胶原N端前肽增加18.7%(25.2升至29.9 ng/mL)。
  • 治疗1年末端骨溶解维持原状未恶化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hajdu-Cheney syndrome (HCS) is an inherited skeletal disorder caused by mutations in the Notch homolog protein 2 gene (NOTCH2). Treatment of this rare disease is challenging because there are no established guidelines worldwide. Previous case reports using bisphosphonates, denosumab, or teriparatide suggested that curative treatment for HCS did not exist yet in terms of preventing the disease progression. Therefore, the efficacy of romosozumab for osteoporosis in patients with HCS needs to be evaluated. Herein, we report the case of a 43-year-old woman who had progressive acro-osteolysis and repeated fractures since the age of 29 years. Next-generation sequencing confirmed HCS with a mutation at nucleotide 6758G>A, leading to Trp2253Ter replacement in NOTCH2. Romosozumab treatment was initiated because she had already received bisphosphonate for more than 10 years at other hospitals. After 1 year of romosozumab treatment, the bone mineral density (BMD) increased by 10.2%, 6.3%, and 1.3%, with Z scores of -2.9, -1.6, and -1.2 at the lumbar spine, femoral neck, and total hip, respectively. In addition, C-telopeptide was suppressed by 26.4% (0.121 to 0.089 ng/mL), and procollagen type I N-terminal propeptide increased by 18.7% (25.2 to 29.9 ng/mL). This was the first report of romosozumab treatment in patient with osteoporosis and HCS in Korea. One year of romosozumab treatment provided substantial gains in BMD with maintaining the last acro-osteolytic status without deteriorating, representing a possible treatment option for HCS.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kim KJ, Hong N, Lee S, et al. Exploratory use of romosozumab for osteoporosis in a patient with Hajdu-Cheney syndrome: a case report. Osteoporos Int. 2023. PMID: 36622389. doi:10.1007/s00198-023-06668-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。